Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of active duodenal ulcer,Prophylaxis of recurrent duodenal ulcer,Treatment of active benign gastric ulcer,Prophylaxis of gastric ulcer in patients at risk,Treatment of gastroesophageal reflux disease (GERD),Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Prophylaxis of stress ulcer in critically ill patients,Prevention of aspiration pneumonitis during anesthesia (off-label),Treatment of urticaria (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life: approximately 2 hours in healthy adults; prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Hepatic metabolism via N-oxidation, S-oxidation, and demethylation; major pathway is N-oxidation. CYP450 involvement is minimal; primarily metabolized by flavin-containing monooxygenase (FMO3).
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minor (approximately 10-15% as metabolites).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
13-25% bound to plasma proteins (primarily albumin).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
1.0-2.0 L/kg; large Vd indicates extensive tissue distribution (e.g., muscle, kidney, liver).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: 60-70% (due to first-pass metabolism); intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For Cr Cl 30-50 m L/min: 300 mg IV every 8 hours. For Cr Cl 15-29 m L/min: 300 mg IV every 12 hours. For Cr Cl <15 m L/min: 300 mg IV every 24 hours.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment for Child-Pugh; use caution and reduce dose in severe hepatic impairment based on clinical response, as clearance may be decreased.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates: 5-10 mg/kg IV every 8-12 hours. Infants and children: 5-10 mg/kg IV every 6-8 hours, not to exceed 300 mg per dose. Adolescents: 300 mg IV every 6-8 hours.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Reduce dose based on renal function; start at lower end of dosing range (e.g., 300 mg IV every 12 hours if Cr Cl 30-50 m L/min) and titrate to response. Monitor for CNS side effects.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
May cause confusion, hallucinations, or delirium (especially in elderly, renally impaired, or critically ill patients),May cause hepatotoxicity (elevated liver enzymes, hepatitis),May cause bone marrow suppression (neutropenia, agranulocytosis; rare),May cause bradycardia or cardiac arrhythmias with rapid IV administration,May inhibit cytochrome P450 (CYP1A2, CYP2C19, CYP2D6, CYP3A4) leading to increased levels of coadministered drugs (e.g., warfarin, theophylline, phenytoin),May cause gynecomastia or impotence with prolonged high doses,Use with caution in patients with renal impairment (dose adjustment required)
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to cimetidine or any component of the formulation,Use in patients with porphyria (may precipitate acute attacks),May interfere with vitamin B12 absorption (long-term use associated with deficiency)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Cimetidine may increase absorption of alcohol, leading to higher blood alcohol levels. Avoid alcohol. High-fat meals may slightly decrease absorption, but not clinically significant. No specific food restrictions.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Cimetidine crosses the placenta. First trimester: Limited data; no increased risk of major malformations in prospective studies. Second/third trimester: No consistent evidence of fetal harm, but cimetidine has been associated with transient neonatal hepatic impairment and antiandrogenic effects in animal studies (dose-dependent). Use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Cimetidine is excreted into human breast milk (M/P ratio approximately 0.7). Peak milk levels occur 1-2 hours after dose. Milk levels are ~10-20% of maternal serum levels. Dose equivalent to infant is about 6-10% of maternal weight-adjusted dose. Caution: potential for anticholinergic effects in the infant. Monitor infant for drowsiness, bradycardia, or hypotonia. Alternative agents (e.g., ranitidine) are preferred.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No pharmacokinetic-specific dose adjustments are standard for cimetidine in pregnancy. However, due to increased renal clearance in pregnancy and possible altered hepatic metabolism, consider dosing at the lower end of the effective range (e.g., 300 mg IV q6-8h) and monitor therapeutic response. For continuous infusion, consider dose reduction in renal impairment.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Cimetidine is a potent inhibitor of CYP1A2, CYP2C19, CYP2D6, and CYP3A4, leading to increased serum levels of many drugs including warfarin, theophylline, phenytoin, and lidocaine. In elderly or renally impaired patients, reduce dose to prevent CNS side effects like confusion or hallucinations. Rapid IV administration can cause hypotension or cardiac arrhythmias; infuse over at least 30 minutes. Monitor for elevated serum creatinine initially due to interference with tubular secretion of creatinine.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Do not smoke while taking this medication, as smoking can decrease its effectiveness.,Avoid alcohol consumption, which can worsen stomach irritation.,Inform your doctor about all medications you take, as cimetidine can interact with many drugs.,Report any confusion, dizziness, or unusual bleeding/bruising immediately.,Take exactly as prescribed; do not increase the dose without consulting your healthcare provider.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cimetidine crosses the placenta. First trimester: Limited data; no increased risk of major malformations in prospective studies. Second/third trimester: No consistent evidence of f. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.